Table 1. Survey Respondent Self-Report of HCT Physician, HCT Center, and Patient, and Baseline GVHD and GVHD Prophylaxis Characteristics.
| HCT Physician Characteristics | Number (%) |
|---|---|
| Practice setting | |
| Academic | 192 (87%) |
| Community | 28 (13%) |
| % effort in clinical duties | |
| <20% | 8 (4%) |
| 20% to 39% | 31 (14%) |
| 40% to 59% | 62 (28%) |
| 60% to 79% | 74 (33%) |
| 80% to 100% | 46 (21%) |
| Duration of practice as HCT physician | |
| Fellow/training | 8 (4%) |
| <5 years | 32 (15%) |
| 5 to 9 years | 78 (35%) |
| 10 to 14 years | 34 (15%) |
| 15 to 19 years | 68 (31%) |
| ≥20 years | 0 (0%) |
| Number of HCT faculty in group | |
| <5 | 81 (37%) |
| 5 to 9 | 94 (43%) |
| 10 to 14 | 24 (11%) |
| 15 to 19 | 12 (5%) |
| ≥20 | 10 (5%) |
| Adult | 178 (81%) |
| Pediatric | 43 (19%) |
|
| |
| HCT Center and Patient Characteristics | Number (%) |
|
| |
| # HCT/year | |
| <25 | 39 (18%) |
| 25 to 49 | 56 (25%) |
| 50 to 99 | 61 (28%) |
| 100 to 149 | 29 (13%) |
| 150 to 199 | 9 (4%) |
| ≥200 | 27 (12%) |
| Median age HCT patients | |
| <20 | 36 (17%) |
| 20 to 39 | 20 (9%) |
| 40 to 59 | 156 (72%) |
| ≥60 | 6 (3%) |
| % in remission at HCT | |
| <25% | 3 (1%) |
| 25% to 49% | 27 (12%) |
| 50% to 74% | 72 (33%) |
| 75% to 100% | 117 (53%) |
| % PBSCs | |
| <25% | 35 (16%) |
| 25% to 49% | 19 (9%) |
| 50% to 74% | 55 (25%) |
| 75% to 100% | 109 (50%) |
| % related donors | |
| <25% | 31 (14%) |
| 25% to 49% | 123 (56%) |
| 50% to 74% | 47 (21%) |
| 75% to 100% | 19 (9%) |
| % HLA matched | |
| <25% | 8 (4%) |
| 25% to 49% | 36 (16%) |
| 50% to 74% | 64 (29%) |
| 75% to 100% | 111 (51%) |
| % RIC or NMA | |
| <25% | 23 (10%) |
| 25% to 49% | 84 (38%) |
| 50% to 74% | 87 (40%) |
| 75% to 100% | 26 (12%) |
| % unrelated donor utilizing cord blood | |
| <25% | 169 (78%) |
| 25% to 49% | 24 (11%) |
|
| |
| HCT Center and Patient Characteristics | Number (%) |
|
| |
| 50% to 74% | 16 (7%) |
| 75% to 100% | 9 (4%) |
|
| |
| GVHD Characteristics | Number (%) |
|
| |
| GVHD prophylaxis | |
| CSA/MTX | |
| <20% | 45 (28%) |
| 20% to 29% | 34 (22%) |
| 40% to 59% | 25 (16%) |
| 60% to 79% | 31 (20%) |
| 80% to 100% | 23 (15%) |
| CSA/MMF | |
| <20% | 51 (40%) |
| 20% to 29% | 39 (31%) |
| 40% to 59% | 17 (13%) |
| 60% to 79% | 13 (10%) |
| 80% to 100% | 7 (6%) |
| TAC/MTX | |
| <20% | 29 (21%) |
| 20% to 29% | 31 (23%) |
| 40% to 59% | 27 (20%) |
| 60% to 79% | 29 (21%) |
| 80% to 100% | 21 (15%) |
| TAC/MMF | |
| <20% | 53 (48%) |
| 20% to 29% | 27 (24%) |
| 40% to 59% | 18 (16%) |
| 60% to 79% | 6 (5%) |
| 80% to 100% | 7 (6%) |
| TAC/SIR | |
| <20% | 53 (66%) |
| 20% to 29% | 15 (19%) |
| 40% to 59% | 5 (6%) |
| 60% to 79% | 5 (6%) |
| 80% to 100% | 2 (3%) |
| Proportion with II-IV acute GVHD | |
| <25% | 29 (13%) |
| 25% to 49% | 129 (59%) |
| 50% to 74% | 58 (26%) |
| 75% to 100% | 4 (2%) |
| Proportion with moderate/severe chronic GVHD | |
| <25% | 51 (23%) |
| 25% to 49% | 115 (52%) |
| 50% to 74% | 52 (24%) |
| 75% to 100% | 2 (1%) |
HCT indicates allogeneic hematopoietic cell transplantation; GVHD, graft-versus-host disease; PBSCs, peripheral blood stem cells; HLA, human leukocyte antigen; RIC, reduced-intensity conditioning; NMA, nonmyeloablative; CSA, cyclosporine; MTX, methotrexate; MMF, myco-phenolate mofetil; TAC, tacrolimus; SIR, sirolimus.